Insmed heads into its May 13 Q1 print carrying a bruise that's hard to ignore: the stock fell 26% in a single session on May 7.
That drop — the largest recorded in the earnings history data — came after the company released an announcement that rattled the market. The stock now trades at $101.35, down 38% over the past month and 24% in the past week alone. Yet the lending market isn't flashing distress. Short interest has barely moved, holding near 6.4% of float — up 28% over the past month in absolute share terms, but barely changed day-to-day. Cost to borrow runs at just 0.45%, and availability remains very loose, meaning the borrow market is nowhere near squeezed. Short sellers are present but not piling in aggressively; the move lower has been driven by sellers, not a structural short squeeze in reverse.
Options positioning reflects the post-shock mood rather than pre-earnings alarm. The put/call ratio is running at 0.68, modestly above its 20-day average of 0.61 — a z-score of just 0.79. That's nowhere near a defensive extreme, especially with the 52-week high at 1.44. Options traders are not treating this as a high-fear setup. They appear to be weighing whether the selloff has priced in the bad news rather than bracing for a new leg down.
The Street has not abandoned the stock, but it has trimmed its ambitions. RBC Capital and Wells Fargo both cut their price targets on May 8 — RBC to $205 from $220, Wells Fargo to $160 from $177 — while maintaining positive ratings. The consensus remains firmly in buy territory, with 17 buy ratings and a mean target of $207.60, implying roughly double the current price. That gap is striking. Bulls point to Brinsupri's bronchiectasis launch, where early physician feedback has reportedly been positive, and the runway for expansion into adjacent respiratory indications. Bears flag that a pre-commercial-stage cash burn — operating cashflow of roughly -$580 million annually — makes execution risk real, and any hiccup in the Brinsupri ramp would be hard to absorb at this valuation. The enterprise value still sits above $23 billion against estimated revenue of $1.7 billion, making the stock an unforgiving hold.
The CEO, Will Lewis, sold roughly $1.47 million of stock across multiple tranches on May 4 — just days before the crash — following further sales on April 16. The 90-day net position, however, is a net buy of 191,362 shares worth nearly $30 million at cost, suggesting the recent sales are likely part of a scheduled plan rather than a directional call. Major institutions including Vanguard, JPMorgan Asset Management, BlackRock, and Fidelity have all added to positions in recent filings, providing a relatively stable ownership base heading into the report.
The May 13 print will test whether Brinsupri's commercial trajectory is strong enough to justify rebuilding confidence at a stock price now half of where it traded just weeks ago.
See the live data behind this article on ORTEX.
Open INSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
